Bdparp 150mg Tablet

Prostate cancer

Pancreatic cancer, Breast cancer, Ovarian cancer

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Bdparp 100mg tablet. Still, they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Bdparp 100mg tablet are:

Headache,

Fever

Loss of appetite

Pain in the eyes

Blurred vision

High blood pressure

red and itchy eyes

lack of sleep.

Vomiting

Indigestion

Nausea diarrhea, or constipation

blood in the urine or a burning sensation while urinating

hair loss

Bdparp 100mg tablets should never be used for self-medication; instead, they should always be used as directed by a physician. As prescribed by the physician, it can be taken with or without food. Your doctor will decide on the amount and timing of the  Bdparp 100mg based on your condition and other factors. For best results, the Bdparp 100mg tablet should be swallowed rather than chewed, opened, or crushed. It is an oral drug that should be taken as prescribed by the physician at the same time each day.

Bdparp 100mg tablet works by blocking the repair mechanism of DNA, as a result growth of cancer cells stops. The tablet inhibits PARP (poly-ADP-Ribose Polymerases), which belongs to the family of proteins that play an important role in genomic stability, DNA repair, and cellular stress responses. The enzymes repair the single-strand DNA breaks (SSBs). Bdparp 100mg tablet inhibits the working of PARP enzymes, which hinders the growth and development of cancer cells.

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., & Tutt, A. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet, 376(9737), 245-251.

Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2024). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. & Carmichael, J. (2020). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.

van der Noll, R., Jager, A., Ang, J. E., Marchetti, S., Mergui-Roelvink, M. W., de Bono, J. S., & Schellens, J. H. (2020). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs, 38(4), 1096-1107.

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T.,& Tamura, T. (2020). A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer science, 103(3), 504-509.